NCT00667641已完成1 期
Phase I Study of Paclitaxel (Taxol) and Bortezomib (Velcade) in Patients With Refractory Solid Tumor Malignancies Involving an Activated MAPK Pathway
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- Maximum tolerated dose of paclitaxel in combination with bortezomib
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving paclitaxel together with bortezomib may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of paclitaxel and bortezomib in treating patients with metastatic or unresectable malignant solid tumors.
详细描述
OBJECTIVES:
Primary
- To identify the maximum tolerated dose of paclitaxel in combination with bortezomib in patients with metastatic or unresectable solid tumor malignancies that involve an activated Ras/Raf/MAPK pathway.
Secondary
- To assess the toxicity of this regimen.
- To assess tumor response in these patients.
- To determine whether Bim is upregulated in peripheral blood mononuclear cells obtained from patients treated with this regimen.
- To correlate markers of Ras/Raf/MAPK pathway activation in fresh or archived tumor tissue with clinical response in these patients.
- To perform pharmacokinetic (PK) studies to determine whether bortezomib alters paclitaxel PK parameters.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically confirmed malignant solid tumor that involves an activated Ras/Raf/MAPK pathway, including the following:
- •Breast cancer
- •Prostate cancer
- •Colon cancer
- •Pancreatic cancer
- •Ovarian cancer
- •Non-small cell lung cancer
- •Papillary thyroid cancer
- •Metastatic or unresectable disease
- •Standard curative or palliative measures do not exist or are no longer effective
- •No newly diagnosed, untreated, or uncontrolled brain metastases
- •PATIENT CHARACTERISTICS:
- •ECOG performance status 0-2
- •ANC ≥ 1,500/μL
- •WBC ≥ 3,500/μL
- •Platelet count ≥ 100,000/μL
- •Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
- •AST/ALT ≤ 2.5 times ULN (≤ 5 times ULN for tumor involvement of the liver)
- •Creatinine ≤ 2 times ULN
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception
- •No neuropathy ≥ grade 1 with pain within the past 14 days
- •No active infections
- •No myocardial infarction within the past 6 months
- •No NYHA class III or IV heart failure
- •No uncontrolled angina
- •No severe uncontrolled ventricular arrhythmias
- •No evidence of acute ischemia or active conduction system abnormalities by ECG
- •Any ECG abnormality at screening must be documented by the investigator as not medically relevant
- •No hypersensitivity to bortezomib, boron, or mannitol
- •No serious medical or psychiatric illness likely to interfere with study participation
- •PRIOR CONCURRENT THERAPY:
- •Prior paclitaxel or bortezomib allowed
- •At least 4 weeks since prior chemotherapy and/or radiotherapy
- •More than 14 days since other prior investigational drugs
- •No other concurrent investigational agents
- •No other concurrent anticancer agents, including chemotherapy and biologic agents
- •No concurrent recombinant interleukin-11 (Neumega®)
排除标准
- 未提供
结局指标
主要结局
Maximum tolerated dose of paclitaxel in combination with bortezomib
时间窗: 2 years
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast CancerStage IIIC Breast CancerStage IV Breast CancerMale Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastRecurrent Breast CancerNCT01288261University of Arizona14
Unknown
2 期
Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast CancerBreast CancerNCT00499525Northwestern University180
已完成
2 期
Paclitaxel in Treating Patients With Locally Advanced or Metastatic Soft Tissue Angiosarcoma or Lymphangiosarcoma That Cannot Be Removed By SurgerySarcomaNCT00217607UNICANCER30
Unknown
2 期
Combination Chemotherapy in Treating Men With Germ Cell CancerExtragonadal Germ Cell TumorTesticular Germ Cell TumorTeratomaNCT00003643European Organisation for Research and Treatment of Cancer - EORTC498
已完成
不适用
Paclitaxel and Radiation Therapy in Treating Patients Undergoing Surgery for Stage II or Stage III Breast CancerBreast CancerNCT00647218Vanderbilt-Ingram Cancer Center38